了解处方实践和患者经验 氨酶系统抑制剂 在慢性病中使用:一项定性研究
Jennifer Arney1,2, L Parker Gregg1,3,4, Sheena Wydermyer5
1Michael E. DeBakey VA Medical Center Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas, USA.
Cardiorenal medicine
|December 27, 2023
概括
在慢性病 (CKD) 中,临床医生和患者对抗胰岛素转化酶抑制剂 (ACEI) 和胰岛素受体抑制剂 (ARB) 的知识缺口. 解决这些差距和障碍是改善ACEI/ARB使用和患者结果的关键.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- ангиотензин转化酶抑制剂 (ACEI) 和 ангиотензин受体阻断剂 (ARB) 对于治疗慢性病 (CKD) 至关重要,但未得到充分利用.
- 在CKD患者中,ACEI/ARB中止和不重新开始治疗的原因尚不清楚.
研究的目的:
- 探索临床医生和患者关于ACEI/ARB在CKD中的使用的经验和看法.
- 确定在CKD中最佳的ACEI/ARB处方和管理的障碍和促进者.
主要方法:
- 定性研究涉及采访15名医疗保健临床医生和退伍军人事务医疗保健系统的10名患者.
- 参与者已经记录了与ACEI/ARB相关的副作用.
- 专题分析被用来确定与处方决策,患者教育和准则遵守相关的关键主题.
主要成果:
- 临床医生认识到ACEI/ARB对CKD中血压和脏保护的重要性,特别是对于糖尿病患者.
- 关于CKD状态和ACEI/ARB治疗的目的,患者知识存在重大差距.
- 临床医生的处方实践和对指南的理解各不相同,并确定了最佳药物管理的障碍.
结论:
- 改善在CKD中的ACEI/ARB利用需要解决患者和临床医生的知识差距.
- 建议开发一个决策支持工具,以帮助临床医生为慢性病患者开处方和管理ACEI/ARB.
- 需要有针对性的干预措施来改善高风险CKD患者的长期结果.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
632
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
632
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
645
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
645
01:17Factors Affecting Renal Clearance: Renal Impairment
95
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
95
01:11Renal Failure: Dose Adjustments
94
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
94
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
735
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
735